For the Quarter Ending June 2026
Erythromycin Prices in North America
- In United States, the Erythromycin Price Index rose quarter-over-quarter in Q2 2026, influenced by various market dynamics.
- Erythromycin production costs increased in Q2 2026, driven by a 5.5% PPI year-over-year in June 2026.
- Demand for effective antibiotics showed positive trends in Q2 2026, supported by robust retail sales of 6.9% in May 2026.
- Consumer purchasing power was impacted by 3.5% CPI year-over-year in June 2026, affecting non-essential Erythromycin demand.
- Industrial electricity costs trended upward in April 2026; natural gas prices softened, impacting production costs.
- U.S. industrial production grew sluggishly at 0.7% year-over-year in June 2026, reflecting a less robust economic environment.
- Low unemployment (4.2% in June 2026) and moderate consumer confidence (91.2) supported healthcare affordability.
- Global pharmaceutical supply chains experienced disruptions in Q2 2026, impacting key Erythromycin ingredients.
Why did the price of Erythromycin change in June 2026 in North America?
- Producer inflation, at 5.5% in June 2026, increased Erythromycin manufacturing costs.
- Industrial electricity costs trended upward in April 2026, adding to production expenses.
- Robust retail sales, up 6.9% in May 2026, supported Erythromycin demand.
Erythromycin Prices in APAC
- In China, the Erythromycin Price Index remained stable quarter-over-quarter in Q2 2026, influenced by weak consumer demand.
- Erythromycin production costs increased in Q2 2026, driven by a 4.1% rise in producer prices in June 2026.
- Demand for Erythromycin faced headwinds in Q2 2026, as retail sales grew 1.0% in June 2026.
- In India, the average price of Erythromycin is USD 48808/MT.
- China's manufacturing sector expanded in June 2026, supporting stable supply chains for Erythromycin.
- Industrial production grew by 5.3% in June 2026, indicating robust manufacturing activity for inputs.
- Antibiotic exports from China declined from April to May 2026; imports increased during the same period.
- The healthcare sector underperformed broader markets in 2026 YTD, impacting pharmaceutical revenue in Q2 2026.
- Weak inflationary pressure, with CPI at 1.0% in June 2026, limited Erythromycin pricing power.
Why did the price of Erythromycin change in June 2026 in APAC?
- Weak consumer demand (1.0% retail sales growth in June 2026) limited Erythromycin pricing power.
- Rising input costs (4.1% producer price increase in June 2026) pressured Erythromycin production economics.
- Declining antibiotic exports (April-May 2026) and increased imports impacted market balance.
Erythromycin Prices in Europe
- In Germany, the Erythromycin Price Index rose quarter-over-quarter in Q2 2026, driven by rising production costs and supply disruptions.
- Erythromycin production costs increased as producer prices for industrial products were 2.2% higher in May 2026.
- Consumer prices rose by 2.3% year-on-year in June 2026, reflecting general cost increases impacting operations.
- Industrial production in Germany remained unchanged at 0.0% in May 2026, indicating a stagnant economic environment.
- The Manufacturing Index showed a contracting trend in June 2026, signaling a slowdown in industrial activity.
- Consumer confidence was negative at -14.6% in June 2026, impacting demand for discretionary Erythromycin products.
- Elevated and volatile natural gas and electricity prices throughout Q2 2026 impacted Erythromycin production expenses.
- Supply chain bottlenecks and reported shortages affected German industrial companies during Q2 2026, constraining availability.
- Retail sales increased by 1.8% in May 2026, while unemployment remained stable at 3.8% in May 2026.
Why did the price of Erythromycin change in June 2026 in Europe?
- Producer prices for industrial products rose by 2.2% in May 2026, increasing Erythromycin manufacturing costs.
- Elevated and volatile natural gas and electricity prices in Q2 2026 raised energy-related production expenses.
- Supply chain bottlenecks and reported shortages in May 2026 constrained availability, contributing to upward price pressure.
For the Quarter Ending March 2026
Erythromycin Prices in North America
- In United States, the Erythromycin Price Index rose quarter-over-quarter in Q1 2026, driven by severe supply shortages.
- Headline CPI reached 3.3% and retail sales grew 4.0% in March 2026, supporting steady consumer pharmacy purchasing.
- The Erythromycin Production Cost Trend declined as corn feedstock costs weakened in February 2026, easing fermentation expenses.
- The Manufacturing Index expanded and producer prices rose 4.0% in March 2026, increasing active pharmaceutical ingredient expenses.
- Industrial production grew 0.7%, unemployment stabilized at 4.3%, and consumer confidence hit 91.8 points in March 2026.
- The Erythromycin Demand Outlook softened as acute respiratory illness visits decreased across the country in March 2026.
- Pharmacy and hospital inventories of erythromycin injections remained severely constrained due to limited manufacturing capacity in Q1 2026.
- The Erythromycin Price Forecast indicated strong upward pressure throughout Q1 2026 as supply shortages outweighed softening patient demand.
Why did the price of Erythromycin change in March 2026 in North America?
- Domestic supply of erythromycin faced ongoing shortages due to limited manufacturing capacity in Q1 2026.
- Elevated producer prices rose 4.0% in March 2026, significantly increasing active pharmaceutical ingredient manufacturing expenses.
- Pharmacy and hospital inventories of erythromycin injections and ointments remained severely constrained in Q1 2026.
Erythromycin Prices in APAC
- In China, the Erythromycin Price Index rose quarter-over-quarter in Q1 2026, driven by surging feedstock costs.
- The Erythromycin Production Cost Trend increased in March 2026 as the Producer Price Index rose 0.5%.
- Corn starch and soybean meal feedstock costs for Erythromycin production surged significantly during Q1 2026.
- The Erythromycin Demand Outlook strengthened in March 2026, supported by a 5.7% Industrial Production increase and an Expanded Manufacturing Index.
- A 1.0% Consumer Price Index rise and 1.7% retail sales growth in March 2026 stabilized pharmaceutical demand.
- An unemployment rate of 5.4% in March 2026 and a 91.6 consumer confidence index in February 2026 constrained spending.
- Soybean meal feedstock inventories for Erythromycin fermentation tightened in February 2026 due to weakened import volumes.
- The Erythromycin Price Forecast remained elevated in Q1 2026 as export volumes to Southeast Asia stabilized in January 2026.
Why did the price of Erythromycin change in March 2026 in APAC?
- Soybean meal nitrogen-source feedstock costs for Erythromycin surged due to tightened supplies in March 2026.
- Veterinary sector demand for Erythromycin fermentation feedstocks strengthened alongside terminal breeding industry in March 2026.
- Erythromycin feedstock processing operations halted completely due to scheduled facility maintenance procedures in February 2026.
Erythromycin Prices in Europe
- In Germany, the Erythromycin Price Index fell quarter-over-quarter in Q1 2026, driven by weakened natural gas prices.
- The producer price index declined by -0.2% in March 2026, easing the Erythromycin Production Cost Trend.
- Consumer inflation rose 2.7% in March 2026, impacting purchasing power but maintaining stable Erythromycin Demand Outlook.
- Retail sales dropped -2.0% and unemployment held at 4.0% in March 2026, reflecting broader economic stagnation.
- The Manufacturing Index remained contracting in March 2026, while industrial production stagnated at 0.0% in February 2026.
- Household and government consumption expenditure strengthened in Q1 2026, supporting broader pharmaceutical and Erythromycin demand.
- European natural gas prices weakened in early Q1 2026, easing energy-intensive fermentation costs for Erythromycin.
- German natural gas storage levels plummeted to historic lows in March 2026, tightening the energy supply buffer.
- Manufacturing stock of orders strengthened in February 2026, providing a stable foundation for the Erythromycin Price Forecast.
Why did the price of Erythromycin change in March 2026 in Europe?
- European natural gas prices weakened in early Q1 2026, reducing energy-intensive fermentation costs for Erythromycin.
- The producer price index declined by -0.2% in March 2026, providing relief to industrial input costs.
- Household and government consumption expenditure strengthened in Q1 2026, supporting stable pharmaceutical and Erythromycin demand.
For the Quarter Ending December 2025
Erythromycin Prices in North America
- In the United States, the Erythromycin Price Index rose quarter-over-quarter in Q4 2025, influenced by elevated natural gas prices.
- Erythromycin production costs increased in Q4 2025, as the Producer Price Index rose 3.0% year-over-year in November 2025.
- Erythromycin demand strengthened in Q4 2025, supported by a 2.0% year-over-year industrial production increase in December 2025.
- The Erythromycin demand outlook was positive, with retail sales increasing 3.3% year-over-year in November 2025.
- Feedstock costs for Erythromycin, including corn and soybean meal, weakened during Fall 2025, partially offsetting rising expenses.
- Natural gas prices were elevated in early December 2025, contributing to higher energy costs for Erythromycin manufacturing.
- The pharmaceutical sector's market performance strengthened in Q4 2025, positively impacting Erythromycin demand.
- A 4.4% unemployment rate in December 2025 supported consumer disposable income, bolstering Erythromycin demand.
- The Consumer Price Index rose 2.7% year-over-year in December 2025, indicating general inflation impacting Erythromycin production.
Why did the price of Erythromycin change in December 2025 in North America?
- Elevated natural gas prices in early December 2025 increased energy inputs for Erythromycin production.
- Rising Producer Price Index (3.0% YoY in November 2025) indicated higher input costs for manufacturers.
- Stronger pharmaceutical sector performance in Q4 2025 boosted overall demand for Erythromycin.
Erythromycin Prices in APAC
- In China, the Erythromycin Price Index declined quarter-over-quarter in Q4 2025, influenced by falling producer prices and ample feedstock inventories.
- Erythromycin production costs decreased in Q4 2025 as liquid glucose prices experienced a downturn in November and December 2025.
- The Erythromycin demand outlook remained robust in 2025, supported by overall pharmaceutical market growth and increased clinical trials.
- China's Manufacturing Index expanded in December 2025, and industrial production grew by 5.2% year-over-year in December 2025.
- Inventories of liquid glucose were ample in November and December 2025, prompting suppliers to reduce offers for excess stock.
- Weak consumer demand, with CPI at 0.8% and retail sales growth at 0.9% in December 2025, limited pricing power.
- The broader chemical sector in Asia, including China, continued to grapple with overcapacity in October 2025.
- Erythromycin price forecast suggests continued downward pressure due to sustained overcapacity and declining input costs in Q4 2025.
Why did the price of Erythromycin change in December 2025 in APAC?
- Producer prices declined by 1.9% in December 2025, reducing input costs for Erythromycin production.
- Liquid glucose prices experienced a downturn in November and December 2025, driven by ample inventories.
- Weak consumer demand, indicated by low CPI (0.8%) and retail sales growth (0.9%) in December 2025, limited pricing power.
Erythromycin Prices in Europe
- In Germany, the Erythromycin Price Index remained stable quarter-over-quarter in Q4 2025, influenced by mixed macroeconomic signals.
- Erythromycin production costs faced upward pressure from comparatively high natural gas prices in Germany during Q4 2025.
- However, falling industrial product prices, with PPI declining by 2.5% in December 2025, mitigated overall production cost increases.
- Erythromycin demand outlook was supported by moderate pharmaceutical market growth in Germany during Q4 2025.
- Consumer confidence, at -17.5 in December 2025, indicated widespread pessimism, impacting non-essential Erythromycin demand.
- The Manufacturing Index trended contracting in December 2025, signaling a broader slowdown in industrial activity.
- Industrial production increased by 0.8% in October 2025, providing some stability for Erythromycin supply chain capabilities.
- Retail sales rose by 1.1% in November 2025, offering slight support for over-the-counter Erythromycin applications.
- Germany's pharmaceutical industry strengthened supply chain resilience in 2025 through investments in local production.
Why did the price of Erythromycin change in December 2025 in Europe?
- Falling industrial product prices, with PPI declining by 2.5% in December 2025, eased Erythromycin production costs.
- Comparatively high natural gas prices in Germany during Q4 2025 exerted upward pressure on Erythromycin manufacturing expenses.
- A contracting Manufacturing Index in December 2025 suggested a cautious economic environment for Erythromycin demand.
For the Quarter Ending September 2025
Erythromycin Prices in North America
- In United States, the Erythromycin Price Index rose quarter-over-quarter in Q3 2025, influenced by increasing production costs.
- Erythromycin production costs increased during Q3 2025, influenced by a 2.6% PPI rise in August and 3.0% CPI in September.
- Strengthening industrial electricity prices in September 2025 further contributed to higher Erythromycin manufacturing expenses.
- Erythromycin demand remained robust in 2025, supported by strong general pharmaceutical demand trends.
- A 5.42% increase in retail sales and a 4.3% unemployment rate in September 2025 bolstered Erythromycin demand.
- Overall chemical supply faced overcapacity in Q3 2025, with industrial production rising only 0.1% in September.
- Businesses actively reduced accumulated inventories in the latter half of 2025, affecting supply chain dynamics.
- US chemical exports experienced a downturn in 2025, while imports eased, impacting trade flows for related chemicals.
Why did the price of Erythromycin change in September 2025 in North America?
- Rising input costs, with a 2.6% PPI increase in August 2025, elevated Erythromycin production expenses.
- Strengthening industrial electricity prices in September 2025 directly contributed to higher manufacturing costs.
- Robust pharmaceutical demand, supported by strong retail sales (5.42% in September 2025), offset some cost pressures.
Erythromycin Prices in APAC
- In China, the Erythromycin Price Index fell quarter-over-quarter in Q3 2025, due to falling factory-gate prices and subdued domestic demand.
- Erythromycin production costs softened in Q3 2025, driven by declining sugar feedstock expenses, despite slight electricity price rises.
- Pharmaceutical demand for Erythromycin strengthened in Q3 2025, contrasting with contracting manufacturing activity.
- China's industrial production increased by 6.5% year-on-year in September 2025, supporting veterinary applications demand.
- Consumer confidence remained pessimistic at 89.6 in September 2025, impacting discretionary healthcare spending.
- The Manufacturing Index contracted in September 2025, reflecting a slowdown in overall industrial activity.
- Strong pharmaceutical raw material exports from China in Q3 2025 indicated robust international demand.
- Raw material inventories for Erythromycin declined in July 2025, with the rate of decline narrowing by September.
- Trade tensions intensified in August 2025, introducing new tariffs impacting pharmaceutical imports.
Why did the price of Erythromycin change in September 2025 in APAC?
- Falling factory-gate prices, indicated by a -2.3% PPI year-on-year in September 2025, pressured Erythromycin pricing.
- Subdued domestic demand, with consumer confidence at 89.6 in September 2025, limited pricing power.
- Softening sugar feedstock costs in Q3 2025 contributed to lower production expenses for Erythromycin.
Erythromycin Prices in Europe
- In Germany, the Erythromycin Price Index fell in Q3 2025, influenced by a 1.7% decline in September 2025 PPI.
- Erythromycin production costs decreased during Q3 2025, driven by falling liquid glucose feedstock and global sugar prices.
- Demand for Erythromycin was supported by robust German healthcare spending and a 0.8% rise in September 2025 retail sales.
- Erythromycin production faced headwinds in Q3 2025, with industrial production contracting 1.0% year-over-year in September 2025.
- The Manufacturing Index trended contracting in September 2025, indicating a slowdown in the broader German manufacturing sector.
- Rising Consumer Price Index (CPI) of 2.4% in September 2025 signaled higher operational costs for Erythromycin producers.
- Carbon allowance costs in the EU-ETS increased during Q3 2025, adding upward pressure on Erythromycin operational expenses.
- Erythromycin demand outlook remained stable, bolstered by a low unemployment rate of 3.9% in September 2025.
Why did the price of Erythromycin change in September 2025 in Europe?
- Declining Producer Price Index (-1.7%) in September 2025 reduced Erythromycin input costs.
- Liquid glucose feedstock and global sugar prices experienced mild declines in Q3 2025.
- Increased carbon allowance costs in Q3 2025 added upward pressure on Erythromycin production.
